ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 831.8 USD | -0.10% |
|
+2.49% | +42.69% |
| 01:00am | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
| Jun. 05 | Health Care Climbs on Obesity-Drug Bets - Health Care Roundup | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.8
USD
Average target price
852.5
USD
Spread / Average Target
+2.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +42.69% | 750B | |
| +34.11% | 606B | |
| -6.87% | 356B | |
| +18.74% | 326B | |
| +6.76% | 286B | |
| +18.08% | 246B | |
| -3.44% | 213B | |
| +11.35% | 213B | |
| +2.64% | 167B | |
| +6.72% | 165B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Redburn Atlantic Adjusts Eli Lilly Price Target to $600 From $540
